Ann Pediatr Endocrinol Metab.  2015 Jun;20(2):74-78. 10.6065/apem.2015.20.2.74.

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol

• Lee JE

• KMID: 2368989
• DOI: http://doi.org/10.6065/apem.2015.20.2.74

Abstract

The growing attention to alternative glycemic biomarkers including fructosamine, glycated albumin (GA), 1,5-anhydroglucitol (1,5-AG), is attributable to the limitations of the glycated hemoglobin (HbA1c) assay. It is important to recognize the conditions in which HbA1c levels may be difficult to interpret. Serum fructosamine and GA have been proposed useful tools for monitoring of short-term glycemic control. These biomarkers not only reflect well glycemic control in hematologic disorder, but also represent postprandial glucose fluctuation. Serum 1,5-AG may be useful for estimating within-day glucose variation. Use of these nontraditional tests can be more helpful in the management of diabetes as complement traditional measures. Further larger cohort studies are warranted to determine whether nontraditional biomarkers have potential utility for early diagnosis, management of diabetes, and prevention of diabetic complications.

Keyword

Diabetes mellitus; Fructosamine; Glycosylated serum albumin; 1,5-anhydroglucitol; Biological markers

MeSH Terms

Biological Markers*
Cohort Studies
Complement System Proteins
Diabetes Complications
Diabetes Mellitus
Early Diagnosis
Fructosamine*
Glucose
Hemoglobin A, Glycosylated
Biological Markers
Complement System Proteins
Fructosamine
Glucose

Reference

1. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care. 1995; 18:896–909. PMID: 7555528.

2. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327–1334. PMID: 19502545.

3. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO Consultation. Geneva: World Health Organization;2011.

4. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014; 29:388–394. PMID: 24002631.

5. Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep. 2014; 14:548. PMID: 25249070.

6. National Glycohemoglobin Standardization Program (NGSP). Factors that Interfere with HbA1c test results [Internet]. NGSP;c2011. cited 2015 May 20. Available from: http://www.ngsp.org/factors.asp.

7. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis. 2003; 37:e53–e56. PMID: 12905153.

8. Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy. 2009; 29:468–472. PMID: 19323622.

9. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004; 44:715–719. PMID: 15384023.

10. Suzuki S, Koga M, Niizeki N, Furuya A, Matsuo K, Tanahashi Y, et al. Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants. Pediatr Diabetes. 2013; 14:267–272. PMID: 23350671.

11. Suzuki S, Koga M, Amamiya S, Nakao A, Wada K, Okuhara K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia. 2011; 54:2247–2253. PMID: 21644010.

12. Koga M, Murai J, Saito H, Kasayama S. Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes. J Diabetes Investig. 2011; 2:304–309.

13. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000; 342:301–307. PMID: 10655528.

14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977–986. PMID: 8366922.

15. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993; 341:1306–1309. PMID: 8098449.

16. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993; 329:304–309. PMID: 8147960.

17. Mosca A, Carenini A, Zoppi F, Carpinelli A, Banfi G, Ceriotti F, et al. Plasma protein glycation as measured by fructosamine assay. Clin Chem. 1987; 33:1141–1146. PMID: 3594841.

18. Pandya HC, Livingstone S, Colgan ME, Percy-Robb IW, Frier BM. Serum fructosamine as an index of glycaemia: comparison with glycated haemoglobin in diabetic and non-diabetic individuals. Pract Diabetes Int. 1987; 4:126–128.

19. Narbonne H, Renacco E, Pradel V, Portugal H, Vialettes B. Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab. 2001; 27(5 Pt 1):598–603. PMID: 11694860.

20. Matsumoto H, Murase-Mishiba Y, Yamamoto N, Sugitatsu-Nakatsukasa S, Shibasaki S, Sano H, et al. Glycated albumin to glycated hemoglobin ratio is a sensitive indicator of blood glucose variability in patients with fulminant type 1 diabetes. Intern Med. 2012; 51:1315–1321. PMID: 22687835.

21. Howey JE, Browning MC, Fraser CG. Assay of serum fructosamine that minimizes standardization and matrix problems: use to assess components of biological variation. Clin Chem. 1987; 33(2 Pt 1):269–272. PMID: 3802511.

22. Miyazaki A, Kohzuma T, Kasayama S, Koga M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann Clin Biochem. 2012; 49(Pt 5):441–444. PMID: 22715294.

23. Kim D, Kim KJ, Huh JH, Lee BW, Kang ES, Cha BS, et al. The ratio of glycated albumin to glycated haemoglobin correlates with insulin secretory function. Clin Endocrinol (Oxf). 2012; 77:679–683. PMID: 22150917.

24. Koga M, Hashimoto K, Murai J, Saito H, Mukai M, Ikegame K, et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta. 2011; 412:253–257. PMID: 20965159.

25. Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin Chem. 2012; 58:1648–1655. PMID: 23019309.

26. Lee JW, Kim HJ, Kwon YS, Jun YH, Kim SK, Choi JW, et al. Serum glycated albumin as a new glycemic marker in pediatric diabetes. Ann Pediatr Endocrinol Metab. 2013; 18:208–213. PMID: 24904879.

27. Shin YS, Park J, Kang DS, Yu J. Significance of the measurement of serum fructosamine in the management of childhood diabetes. Int J Pediatr Endocrinol. 2013; 2013(Suppl 1):P36.

28. Koga M, Murai J, Morita S, Saito H, Kasayama S. Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabetes Complications. 2013; 27:211–213. PMID: 23312788.

29. Hirsch IB, Brownlee M. Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. JAMA. 2010; 303:2291–2292. PMID: 20530784.

30. Chon S, Lee YJ, Fraterrigo G, Pozzilli P, Choi MC, Kwon MK, et al. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus. Diabetes Technol Ther. 2013; 15:455–460. PMID: 23617251.

31. Koga M, Murai J, Saito H, Otsuki M, Kasayama S. Evaluation of the glycated albumin/HbA1c ratio by stage of diabetic nephropathy. Diabetol Int. 2011; 2:141–145.

32. Koga M, Murai J, Saito H, Matsumoto S, Kasayama S. Effects of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract. 2009; 84:163–167. PMID: 19243849.

33. Suzuki S, Koga M, Takahashi H, Matsuo K, Tanahashi Y, Azuma H. Glycated albumin in patients with neonatal diabetes mellitus is apparently low in relation to glycemia compared with that in patients with type 1 diabetes mellitus. Horm Res Paediatr. 2012; 77:273–276. PMID: 22538993.

34. Koga M. Glycated albumin: clinical usefulness. Clin Chim Acta. 2014; 433:96–104. PMID: 24631132.

35. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J. 2006; 53:387–391. PMID: 16717395.

36. Suzuki S, Koga M, Niizeki N, Furuya A, Takahashi H, Matsuo K, et al. Glycated albumin is lower in infants than in adults and correlated with both age and serum albumin. Pediatr Diabetes. 2013; 14:25–30. PMID: 22816963.

37. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994; 24(Suppl):S261–S268. PMID: 7859616.

38. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5:355–363. PMID: 12828817.

39. Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008; 8:9–19. PMID: 18088226.

40. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, et al. Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes. 1989; 38:723–729. PMID: 2656341.

41. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care. 2008; 31:1534–1535. PMID: 18426859.

42. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, et al. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995; 18:1156–1159. PMID: 7587851.

43. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 2004; 27:1859–1865. PMID: 15277408.

44. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006; 29:1214–1219. PMID: 16731998.

45. Seok H, Huh JH, Kim HM, Lee BW, Kang ES, Lee HC, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J. 2015; 39:164–170. PMID: 25922811.

46. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014; 37:2034–2054. PMID: 24935775.

47. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care. 2012; 35:2265–2270. PMID: 22875225.

48. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011; 93:645–658. PMID: 21167901.

49. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004; 27:1761–1773. PMID: 15220264.